Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Seronegative myasthenia gravis.

Angela Vincent1, John McConville, Maria Elena Farrugia

  • 1Department of Clinical Neurology, University of Oxford, Oxford, United Kingdom.

Seminars in Neurology
|July 2, 2004
PubMed
Summary

Seronegative myasthenia gravis (MG) is complex, with some patients lacking acetylcholine receptor (AChR) antibodies. Further research reveals distinct immunological and clinical subtypes within this group, including those with muscle-specific tyrosine kinase (MuSK) antibodies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relative frequencies of muscle specific kinase antibody myasthenia in 46 centres worldwide.

Brain : a journal of neurology·2026
Same author

Adult-onset PLEC-related congenital myasthenic syndrome-myopathy overlap with upper limb predominant weakness.

Neurogenetics·2026
Same author

Frequent co-occurrence of AChR-positive myasthenia gravis in facioscapulohumeral muscular dystrophy suggests a novel disease association.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Immunotherapy responsive startle with antibodies to voltage gated potassium channels.

BMJ case reports·2025
Same author

Epidemiologic, Clinical, and Radiologic Study of Cerebral Amyloid Angiopathy-Related Inflammation in Northern Ireland.

Neurology·2025
Same author

Subtype-specific atypical B cell profiles in myasthenia gravis reveal distinct immunopathological pathways.

Frontiers in immunology·2025

Area of Science:

  • Neurology
  • Immunology
  • Autoimmune Diseases

Background:

  • Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular transmission.
  • A subset of MG patients, termed seronegative myasthenia gravis (SNMG), lack detectable acetylcholine receptor (AChR) antibodies.
  • Ocular MG frequently presents as seronegative, potentially due to assay sensitivity or ocular muscle susceptibility.

Purpose of the Study:

  • To investigate the heterogeneity of seronegative myasthenia gravis (SNMG).
  • To explore the immunological and clinical characteristics of SNMG patients.
  • To identify potential targets and clinical implications of novel antibodies in SNMG.

Main Methods:

  • Analysis of patient plasma for factors affecting AChR function in vitro.

Related Experiment Videos

  • Detection of antibodies against muscle-specific tyrosine kinase (MuSK).
  • Clinical and immunological characterization of distinct SNMG subgroups.

    • Main Results:

    • SNMG plasma may contain immunoglobulin M (IgM) antibodies impacting AChR function, though the target is unclear.
    • A subset of SNMG patients possess antibodies against MuSK, inhibiting AChR clustering.
    • MuSK antibody-positive SNMG patients often exhibit bulbar weakness and differ clinically and electrophysiologically from MuSK antibody-negative SNMG patients.

    Conclusions:

    • Seronegative myasthenia gravis is immunologically and clinically heterogeneous.
    • Muscle-specific tyrosine kinase (MuSK) antibodies define a distinct subgroup of SNMG with specific clinical features.
    • Further research is needed to elucidate the in vivo role of MuSK antibodies and other factors in SNMG pathogenesis.